Baxter International warned on Friday that hurricane-related disruptions at its North Carolina IV solutions facility could affect its financials through early 2025. Shares of the medical products ...

Tocilizumab treatments in patients with noninfectious uveitis demonstrated high rates of success at 1 year follow ups.

A recent shortage of intravenous solutions underscores the need to address the fragile supply chain for infusion therapy ...

Leqembi is approved for Alzheimer’s patients in multiple territories, but questions remain over its cost-effectiveness.

Read about Baxter's progress in restoring its North Cove facility after Hurricane Helene-related flooding, causing widespread shortages and a $200 million loss.

Now Baxter said it expects to restart a second IV solutions manufacturing line in the coming week ... The plant, which ...

Baxter International cut its annual profit forecast on Friday, citing hurricane-related disruptions at its North Carolina intravenous solutions facility, causing its shares to fall 1.3% in premarket ...

Baxter expects to restart a second IV solutions manufacturing line within the next week, the company announced today. Along ...

Preclinical data demonstrated durable immune responses and tumor growth inhibition with Mural's IL-18 variants, reinforcing ...